(NYSE: JNJ) Johnson & Johnson's forecast annual revenue growth rate of 3.25% is not forecast to beat the US Drug Manufacturers - General industry's average forecast revenue growth rate of 7.29%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 9.57%.
Johnson & Johnson's revenue in 2025 is $89,331,000,000.On average, 6 Wall Street analysts forecast JNJ's revenue for 2025 to be $219,400,159,521,722, with the lowest JNJ revenue forecast at $218,509,950,905,664, and the highest JNJ revenue forecast at $219,907,879,480,763. On average, 6 Wall Street analysts forecast JNJ's revenue for 2026 to be $226,753,978,430,506, with the lowest JNJ revenue forecast at $223,986,173,688,668, and the highest JNJ revenue forecast at $229,613,979,088,249.
In 2027, JNJ is forecast to generate $237,207,481,392,794 in revenue, with the lowest revenue forecast at $233,004,136,338,360 and the highest revenue forecast at $241,819,026,403,304.